TEM Tempus AI, Inc.
Company Analysis
Latest News
Tempus AI Outperforms Clinical Standards, Predicting Cancer Survival with New Model
Tempus AI (NASDAQ: TEM) announced initial results from its multimodal oncology foundation model at the 2026 American Society of Clinical Oncology (ASCO) Annual...
Tempus AI Expands 'Next' Platform for Real-Time Cancer Care Intelligence
Tempus AI expanded its AI-enabled 'Next' platform to deliver real-time clinical intelligence for oncology. The update introduces capabilities for six new...
Tempus AI Upgrades Tempus Hub With Agentic AI, Automating Oncology Workflows
Tempus AI integrated a next-generation agentic AI architecture into its Tempus Hub physician platform. The upgrade provides oncologists with an agent-first...
🟢 TEM surges 4.1% after announcing dozens of studies to be presented at major oncology conference
TEM is trading at $48.07 (+4.1%) after the company announced significant upcoming data presentations. • Tempus announced that 37 abstracts have been accepted...
Tempus AI Launches ArteraAI Prostate Test to Predict Patient Mortality
Tempus AI launched the ArteraAI Prostate Test for patients with metastatic hormone-sensitive prostate cancer. This release marks the first time Tempus has...
🟢 TEM is trading 5.4% up today after announcing validation wins for its Cardiac AI diagnostics platform
TEM is trading 5.4% up today at $45.98 after the company announced significant validation wins for its Cardiac AI diagnostics platform across regulatory and...
🟢 TEM is trading 4.2% up today on technical rebound after recent slide
TEM is trading up 4.2% at $45.44 on a technical rebound and dip-buying interest following a week of steady declines. • The move comes despite a lack of fresh...
🟢 TEM is trading 4% up today, rebounding from last week's slide
TEM is trading 4% up today at $45.38, rebounding from last week’s steady slide and a modest loss on May 18. • There are currently no fresh company-specific...
Tempus AI Expands Bristol Myers Squibb Deal, Optimizing Clinical Trials
Tempus AI expanded its strategic collaboration with Bristol Myers Squibb to improve clinical development success rates. The partnership leverages Tempus’ AI...
Tempus AI Completes $460M Offering of 0.00% Convertible Senior Notes Due 2032
Tempus AI, Inc. has completed a private offering of $460 million in aggregate principal amount of 0.00% Convertible Senior Notes due 2032. This amount includes...
Tempus AI Completes $400 Million Convertible Senior Notes Offering
Tempus AI, Inc. closed an offering of $400 million in convertible senior notes due 2032. The company increased the total from $350 million, reflecting strong...
Tempus AI Closes $400M Upsized Debt Offering to Repay Loans
Tempus AI finalized its upsized offering of $400 million in 0.00% Convertible Senior Notes due 2032. The offering increased from the initial $350 million...
🔴 TEM is trading 5.2% down today amid a broad market selloff and post-earnings pressure
TEM is trading at $45.94 (-5.2%) during Tuesday's session, extending losses following its May 7 earnings report as macro headwinds weigh on the biotech and AI...
🔴 TEM is trading 4% down today as post-earnings losses extend amid broader market weakness
TEM is trading at $46.51 (-4.02%) as post-earnings losses extend amid a broader market selloff. • As of mid-morning May 12, 2026, the stock continues to slide...
Tempus AI Target Slashed to $64, Following Wider Q1 Net Loss
H.C. Wainwright maintained its Buy rating on Tempus AI while lowering the 12-month price target from $95 to $64. This 32.6% reduction follows the company’s...
Tempus AI Grew Revenue 36% and Raised Its Outlook — So Why Are Investors Heading for the Exits?
Shares of Tempus AI slid 5.1% to $46.95 on May 8, extending a punishing 16% decline from their May 1 close of $55.00 — even as the broader Nasdaq rallied...
🔴 TEM falls 5% as Q1 earnings beat is overshadowed by weak guidance
TEM is trading at $46.95 (-5.09%) as the market continues to digest its Q1 2026 earnings report. • While the company beat analyst estimates with revenue of...
🔴 TEM is trading 4.6% down today after announcing $400M convertible note offering
TEM is trading at $47.21 (-4.57%) after the company announced a significant financing event before the market open. • Tempus announced the pricing of $400.0...
Tempus AI offers $350 million in notes, aiming to cut debt costs
Tempus AI announced a private placement of $350 million in convertible senior notes due 2032. The company intends to use net proceeds to repay $307.7 million...
🔴 TEM is trading 5.6% down today as investors weigh GAAP net loss against revenue beat
TEM is trading at $50.50 (-5.6%) as the market reacts to a significant GAAP net loss despite a strong revenue beat and raised full-year guidance. • The...